Research suggests that a drug similar to one under evaluation as a possible cancer treatment might eventually help people born with fragile X syndrome (FXS). The study was published in Neuropsychopharmacology.
Scientists, led by Lee Grimes, PhD, report in the Journal of Experimental Medicine identifying a potential treatment target for an aggressive and deadly blood cancer called acute myeloid leukemia (AML).
Researchers, led by Q. Richard Lu, PhD, report in Developmental Cell that mutation or loss of a gene called CHD8 hinders formation of the sheath in developing oligodendrocytes, causing neurological defects in the animals.
Learn more about the business of science and our expanded Innovation Ventures teams in the Summer 2018 issue of Research Horizons.
Our 2017 Research Annual Report reflects another year of outstanding scientific achievement by our faculty and the Cincinnati Children’s Research Foundation.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2018 Cincinnati Children's Hospital Medical Center. All rights reserved.